Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.58 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.58 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 13/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14865912 | 0.87 | PRKD3 (0.75) | PRKD3PRKD1PRKD2HSD17B10HPGD | |
| SCHEMBL4510827 | 0.87 | PRKD3 (0.77) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4510838 | 0.87 | PRKD3 (0.77) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4510835 | 0.87 | PRKD3 (0.77) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL14866101 | 0.82 | PRKD3 (0.48) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4511925 | 0.82 | PRKD3 (0.52) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4511914 | 0.82 | PRKD3 (0.52) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4518250 | 0.82 | PRKD3 (0.54) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4518259 | 0.82 | PRKD3 (0.54) | PRKD3PRKD1PRKD2MEN1KMT2A | |
| SCHEMBL4511930 | 0.82 | PRKD3 (0.52) | PRKD3PRKD1PRKD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354372-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | THE J. DAVID GLADSTONE INSTITUTES | 2016-12-08 | — | — | US | disclosed |
| US-9359445-B2 | Compositions and methods for treating neurological disorders | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130095113-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354372-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | PKD2, PKD1, CKMT1A; CKMT1B | PRKD3 74/4885PRKD1 62/4885PRKD2 50/4885 |
| US-20130095113-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | PKD2, PKD1, CKMT1A; CKMT1B | PRKD3 74/4885PRKD1 62/4885PRKD2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.